Back

Residual inflammatory risk.

29 August 2022 (14:15 - 14:30)
Organised by:
Congress Presentation Part of: How to deal with residual cardiovascular risk in atherosclerotic disease? New pharmacotherapeutic options Cardiovascular Pharmacotherapy ESC Professional Premium Access ESC Congress 2022

About the speaker

Photo
Professor Wolfgang Koenig

TUM Universitätsklinikum, German Heart Center, Munich (Germany)

4 More presentations in this session

Presentation thumbnail
Residual risk in dyslipidaemias: from statins to PCSK9 inhibitors and beyond.
Professor E. Stroes (Amsterdam, NL)
Slides Video
Presentation thumbnail
Residual thrombotic risk: from monotherapy to dual pathway inhibition.
Professor B. Rocca (Casamassima, IT)
Slides Video
Presentation thumbnail
Residual diabetic risk: from glucose lowering to cardiovascular protection.
Professor N. Marx (Aachen, DE)
Slides Video
Presentation thumbnail
How to deal with residual cardiovascular risk in atherosclerotic disease? New pharmacotherapeutic options – discussion.
Video

Access the full session

Session thumbnail
How to deal with residual cardiovascular risk in atherosclerotic disease? New pharmacotherapeutic options
Video

The Event

Event poster

ESC Congress 2022

29 August 2022 14:15 CET
You may be interested in
thumbnail
Congress Session
Inflammation in atherosclerotic cardiovascular disease (ASCVD): the spark before the fire?
27 August 2022
thumbnail
Congress Presentation
Discussion.
26 August 2022
thumbnail
Congress Presentation
Clinical outcomes according to residual cholesterol and inflammatory risk in patients undergoing PCI
30 August 2024
thumbnail
Congress Presentation
Residual inflammatory risk: what is it and what can we do about it?
14 March 2025

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources